Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Personalized Medicine and Treatment in Inflammatory Bowel Diseases
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Personalized Medicine and Treatment in Inflammatory Bowel Diseases

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: closed (21 March 2026) | Viewed by 1048

Special Issue Editors

Dr. Carmen Monica Preda

E-Mail Website
Guest Editor
1. Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
2. Department of Gastroenterology, Fundeni Clinic Institute, 022328 Bucharest, Romania
Interests: ulcerative colitis; Crohn’s disease; inflammatory bowel diseases; endoscopy
Special Issues, Collections and Topics in MDPI journals
Dr. Cristian George Tieranu

E-Mail Website
Guest Editor
1. Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 010017 Bucharest, Romania
2. Elias Emergency University Hospital, 010017 Bucharest, Romania
Interests: gastroenterology; inflammatory bowel diseases; Crohn’s disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Personalized medicine is transforming the treatment of inflammatory bowel diseases (IBDs), including Crohn’s disease and ulcerative colitis, by allowing us to tailor therapies to individual patient profiles. This approach leverages advancements in genomics, microbiome analysis, and immune profiling to identify biomarkers that predict disease progression and treatment responses. Traditional IBD management often follows a trial-and-error method, but personalized strategies can be designed to optimize efficacy while minimizing side effects. For instance, pharmacogenomics helps determine optimal drug choices (e.g., anti-TNF agents, JAK inhibitors) based on genetic makeup, while microbiome modulation offers insights into diet and probiotic interventions. Machine learning further enhances decision-making through the integration of multi-omics data. There are still challenges to overcome, such as high costs and data interpretation complexities, but there is significant potential for improvements in remission rates and quality of life. As research progresses, personalized medicine shows promise in redefining IBD care, emphasizing precise and patient-specific solutions.

Dr. Carmen Monica Preda
Dr. Cristian George Tieranu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized medicine
  • inflammatory bowel diseases (IBDs)
  • Crohn’s disease
  • ulcerative colitis
  • biomarkers
  • pharmacogenomics
  • microbiome
  • anti-TNF therapy
  • precision medicine
  • machine learning

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 791 KB  
Article
Efficacy of Second-Line Advanced Therapy in Patients with Crohn’s Disease After Failure of a First Anti-TNF: A Descriptive Analysis
by Corina Meianu, Carmen Monica Preda, Mircea Diculescu, Doina Istratescu, Anca Trifan, Alina Tantau, Ana Maria Singeap, Cristian George Tieranu, Horia Minea, Ana-Maria Buzuleac, Lucian Negreanu, Remus Popescu, Andreea Bota, Tudor Stroie, Letitia Tugui, Andreea-Maria Cazimirovitz and Cosmin Alexandru Ciora
J. Clin. Med. 2026, 15(8), 3029; https://doi.org/10.3390/jcm15083029 - 16 Apr 2026
Viewed by 270
Abstract
Introduction: Sequencing therapy for Crohn’s disease (CD) is currently being intensively discussed due to the development of novel drugs and lack of standardized criteria for drug positioning in first- and further-line treatment. The aim of this study was to compare the efficacy of [...] Read more.
Introduction: Sequencing therapy for Crohn’s disease (CD) is currently being intensively discussed due to the development of novel drugs and lack of standardized criteria for drug positioning in first- and further-line treatment. The aim of this study was to compare the efficacy of a second-line advanced therapy in Romanian patients with CD who have failed an anti-TNF agent. Methods: We performed a multicenter retrospective study that included adult patients with CD who had secondary loss of response after an initial response with an anti-TNF drug. The main outcome was clinical remission at 12 weeks of second-line treatment (CDAI < 150). The secondary outcomes included clinical response (decrease in CDAI ≥ 70 points), persistence of therapy at 1 year and rates of adverse events. Results: From 2008 to 2024, 216 patients were either switched to another anti-TNF or swapped to another therapeutic class, due to the failure of a first anti-TNF drug. Secondary lines of treatment included infliximab (IFX), adalimumab (ADA), vedolizumab (VDZ), ustekinumab (UST). The highest rate of clinical remission (81%) was obtained with the sequence ADA-IFX in 26/32 (81%) patients and ADA-UST in 62/82 (76%) patients, followed by IFX-UST in 22/33 (67%) and IFX-ADA 34/51 (67%). Persistence in therapy at 1 year was better for the sequence ADA-UST (73%) and IFX-UST (67%) and ADA-IFX (63%) compared to IFX-ADA (59%) and IFX-VDZ (44%) (p < 0.001). Conclusions: There were significant baseline differences between the treatment groups, so this study represents an unadjusted comparison between the results obtained with different biologics in second-line treatment for Crohn’s disease. In patients with CD who have failed a first anti-TNF, the highest rate of clinical remission at 12 weeks was obtained with second-line IFX and UST whilst vedolizumab showed lower efficacy. UST demonstrated the most favorable long-term treatment persistence at 1 year. Full article
(This article belongs to the Special Issue Personalized Medicine and Treatment in Inflammatory Bowel Diseases)
►▼ Show Figures

Figure 1

14 pages, 278 KB  
Article
Predictors of Stress, Anxiety, Depression and Quality of Life in Patients Diagnosed with Chronic Inflammatory Bowel Disease in Romania: A Cross-Section Observational Case-Report Study
by Oliviu Florentiu Sarb, Adriana Daniela Sarb, Daniel Leucuta, Ciprian Brisc and Alina Ioana Tanțău
J. Clin. Med. 2026, 15(5), 1996; https://doi.org/10.3390/jcm15051996 - 5 Mar 2026
Viewed by 389
Abstract
Background/Objectives: Inflammatory bowel disease (IBD), mainly encompassing Crohn’s disease (CD) and ulcerative colitis (UC), is strongly linked to psychological comorbidities such as depression, anxiety, and stress. These mental health factors negatively impact disease progression, healthcare utilization, and quality of life (QoL). Methods: Participants [...] Read more.
Background/Objectives: Inflammatory bowel disease (IBD), mainly encompassing Crohn’s disease (CD) and ulcerative colitis (UC), is strongly linked to psychological comorbidities such as depression, anxiety, and stress. These mental health factors negatively impact disease progression, healthcare utilization, and quality of life (QoL). Methods: Participants completed the Depression–Anxiety–Stress Scale 21 (DASS-21) and EuroQol (EQ-5D-5L) questionnaires. Statistical analyses included multivariate linear regressions to identify predictors of psychological distress. Results: We conducted a cross-sectional case–control study involving 355 participants: 55 with CD, 90 with UC, and 210 healthy controls. Patients with IBD reported significantly higher levels of stress (p < 0.01), anxiety (p = 0.016), and depression (p < 0.01) compared to controls. Severe or very severe symptoms were more prevalent in those with CD and UC. The relative risk for stress was high (RR = 2.1), and the risk for depression was significantly elevated (RR = 1.54) in the IBD population. Quality-of-life analysis revealed lower EQ visual analog scale scores and increased difficulties across all domains, particularly in emotional well-being and pain. Multivariate analysis showed UC diagnosis, female sex, and corticosteroid use as predictors of higher stress and depression scores, while self-reported rest was consistently protective. Conclusions: This study confirms the psychological burden of IBD and underscores the importance of regular screening for stress, anxiety, and depression in clinical care. Self-reported rest emerged as a key protective factor, suggesting potential benefits from interventions targeting sleep quality and emotional support. Future research should explore longitudinal outcomes and personalized psychological interventions in IBD populations. Full article
(This article belongs to the Special Issue Personalized Medicine and Treatment in Inflammatory Bowel Diseases)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop